Research programme: immunosuppressive and cancer therapy - Cerylid Biosciences

Drug Profile

Research programme: immunosuppressive and cancer therapy - Cerylid Biosciences

Alternative Names: CBL 113; CBL 114; CBL 745; CBL 78; Immunosuppressive and cancer therapy research programme - Cerylid Biosciences

Latest Information Update: 07 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cerylid Biosciences
  • Class
  • Mechanism of Action Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Immunosuppression; Inflammation

Most Recent Events

  • 01 Jul 2004 Preclinical trials in Cancer in Australia (unspecified route)
  • 01 Jul 2004 Preclinical trials in Immunosuppression in Australia (unspecified route)
  • 01 Apr 2004 Preclinical trials in Inflammation in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top